Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals Inc (NQ: RCKT )

16.98 +0.33 (+1.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs
From Rocket Pharmaceuticals
Via Business Wire
Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout... 
Via Benzinga
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Host In-Person Investor and Analyst Event and Webcast on Tuesday, Dec. 14 at 7:30 a.m. ET to Discuss Updated Clinical Data Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Participation in Evercore ISI 4th Annual HEALTHCONx Virtual Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
70 Biggest Movers From Yesterday
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
Rocket Pharma To Test Lower Dose Of Gene Therapy In Genetic Disorder Trial
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced updated data from the Phase 1 trial evaluating a single intravenous infusion of RP-A501, an investigational... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Tricida (NASDAQ:TCDA) shares rose... 
Via Benzinga
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessions 2021
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19... 
Via Benzinga
Rocket Pharma Posts Interim Data From Immunodeficiency Disorder Gene Therapy Trial
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced interim data updates from seven patients from the RP-L201 Phase 1/2 trial for Leukocyte Adhesion Deficiency... 
Via Benzinga
Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces $26.4 Million Private Placement
From Rocket Pharmaceuticals, Inc.
Via Business Wire
FDA Lifts Clinical Hold On Rocket Pharma's X-Linked Inherited Disorder Trial
The 
Via Benzinga
Exposures Product Safety
Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.